# Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension

> **NCT06055452** · PHASE4 · RECRUITING · sponsor: **China National Center for Cardiovascular Diseases** · enrollment: 120 (estimated)

## Conditions studied

- Pre-Heart Failure
- Hypertension

## Interventions

- **DRUG:** Empagliflozin 10 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06055452
- **Lead sponsor:** China National Center for Cardiovascular Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-19
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06055452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06055452, "Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06055452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*